Enhanced car-t cells overexpressing cd200 and uses thereof

By overexpressing the CD200 gene in CAR-T cells and enhancing their cytokine secretion capacity, the problem of insufficient killing and anti-tumor effects of CAR-T therapy has been solved, achieving stronger tumor cell killing and anti-tumor effects.

CN120464631BActive Publication Date: 2026-07-03THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Filing Date
2025-04-23
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

The existing CAR-T therapy still needs improvement in terms of its killing and anti-tumor effects.

Method used

The ability of CAR-T cells to secrete cytokines is enhanced by overexpressing the CD200 gene. The specific methods include constructing a fusion gene containing the CD200 encoding gene and a lentiviral expression vector, transfecting T lymphocytes, and preparing enhanced CAR-T cells.

Benefits of technology

It enhanced the secretion capacity of IFN-γ and TNF-α in CAR-T cells, thereby strengthening their killing function against tumor cells and their anti-tumor effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120464631B_ABST
    Figure CN120464631B_ABST
Patent Text Reader

Abstract

The application provides an enhanced CAR-T cell overexpressing CD200 and an application thereof, and belongs to the technical field of biological medicine. The application provides an application of CD200 in preparation of a product for improving the anti-tumor effect of a CAR-T cell. CD200 can improve the cytokine secretion capacity of a CAR-T cell, thereby improving the killing and anti-tumor effect of the CAR-T cell. The application overexpresses CD200 on a CD19 CAR-T cell, and compared with a conventional CD19 CAR-T cell, has stronger cytokine secretion capacity, and can better play the killing and anti-tumor function.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Chimeric antigen receptor gene engineering vector and immune cells, and applications thereof

    CN110129369A

  • Chimeric antigen receptor gene engineering vector, immune cell modified thereby and application thereof

    WO2019154204A1